Theravance Biopharma TBPH Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Theravance Biopharma's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Theravance Biopharma's accrued expenses?
- Theravance Biopharma (TBPH) reported accrued expenses of $8.73M in Q1 2026.
- How has Theravance Biopharma's accrued expenses changed year-over-year?
- Theravance Biopharma's accrued expenses increased by 62.1% year-over-year, from $5.39M to $8.73M.
- What is the long-term trend for Theravance Biopharma's accrued expenses?
- Over 5 years (2020 to 2025), Theravance Biopharma's accrued expenses has grown at a -18.6% compound annual growth rate (CAGR), from $35.24M to $12.59M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.